R&D Cost Estimate Should Be Studied By FDA, Rep. Brown Tells Commissioner
Executive Summary
FDA should gather its own data on the cost of drug development rather than repeat the industry estimate of $800 mil. per new molecular entity, Rep. Sherrod Brown (D-Ohio) told an IIR conference on generic drugs Oct. 1 in Washington, D.C
You may also be interested in...
R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME
Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials